p = #.# [004]

Related by string. p = #.# [002] * PS . P. . PD . Per . Ping : & P . Pay Per View . Earnings Per Share . Ten Per Cent . Pay Per Click / = [031] . = [003] . = [019] . = [035] . = [047] : Yard Freestyle =-#.# mg dL . target = blank . = js enabled . = Search permaLink . root = string / #.# [010] . #.# [009] . #.# [027] . #.# [022] . #.# [043] : #.# ov #-# . Rs #.# [005] . #.# Advocate promote . #.# ERA . #.# Promote sexually * *

Related by context. Frequent words. (Click for all words.) 87 p = #.# [002] 80 p = 78 P = .# 74 placebo p = 71 % CI #.#-#.# [002] 70 confidence interval CI 70 placebo p 67 n = 67 % CI #.#-#.# [006] 66 65 CI = 65 placebo 61 LVEF 61 secondary endpoint 60 ± 60 mg d 60 postoperatively 60 copies mL 59 free survival PFS 59 mg BID 58 demonstrated statistically significant 58 HbA1c levels 58 statistically significant improvement 58 dyspnea 58 febrile neutropenia 58 statistically significant reduction 58 FOLFOX 57 HCV RNA 57 mg kg 57 evaluable 57 Median survival 57 tiotropium 57 postoperative 56 mg dL 56 primary endpoint 56 mm Hg 56 preoperative 56 nasopharyngitis 56 r = 56 preoperatively 56 plus ribavirin 56 ng mL 56 copies ml 55 etanercept 55 quetiapine 55 statistically significant 55 enoxaparin 55 mmHg 55 symptom severity 55 mg dose 55 mg 54 secondary endpoints 54 g dL 54 mmol L 54 ACR# [002] 54 clopidogrel 54 reach statistical significance 54 glimepiride 54 Adverse events 54 myocardial infarction MI 54 dexamethasone 54 μg 54 monotherapy 53 myocardial infarction 53 evaluable patients 53 FEV1 53 pioglitazone 53 contralateral 53 primary efficacy endpoint 53 histologic 53 fluorouracil 53 ng ml 53 lamivudine 53 adalimumab 52 insulin glargine 52 pruritus 52 trastuzumab 52 analgesia 52 imatinib 52 olanzapine 52 revascularization 52 erythema 52 zoledronic acid 52 treatment emergent adverse 52 asthenia 51 df = 51 mcg 51 valsartan 51 thrombocytopenia 51 mg/m2 51 HbA1c 51 fluoxetine 51 docetaxel 51 51 intraoperative 51 proteinuria 50 mg doses 50 Hb 50 CABG 50 multivariate analysis 50 mL min

Back to home page